Open-label dose-escalation on study of oral 1-octanol in patients with essential tremor

Neurology

Volumn 62, Issue 12, 2004, Pages 2320-2322

  Shill, H A ^a   Bushara, K O ^b   Mari, Z ^a   Reich, M ^a   Hallett, M ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCTANOL;

ACCELEROMETER; ADULT; AGED; AMPLITUDE MODULATION; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL TREMOR; HANDWRITING; HEADACHE; HUMAN; NAUSEA; PRIORITY JOURNAL; TASTE DISORDER; URINARY TRACT INFECTION; XEROSTOMIA;

EID: 2942709755     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.62.12.2320     Document Type: Article

References (10)

1. Rothwell JC. Physiology and anatomy of possible oscillators in the central nervous system. Mov Disord 1998;13(suppl 3):S24-S28.
2. Lamarre Y, Mercier LA. Neurophysiological studies of harmaline-induced tremor in the cat. Can J Physiol Pharmacol 1971;49:1049-1058.
3. Sinclair JG, Lo GF, Harris DP. Ethanol effects on the olivocerebellar system. Can J Physiol Pharmacol 1982;60:610-614.
4. Rappaport MS, Gentry RT, Scheinder DR, Dole VP. Ethanol effects on harmaline-induced tremor and increase of cerebellar cyclic GMP. Life Sci 1984;34:49-56.
5. Sinton CM, Krosser BI, Walton KD, Llinás RR. The effectiveness of different isomers of octanol as blockers of harmaline-induced tremor. Pflugers Arch 1989;414:31-36.
6. McCreery MJ, Hunt WA. Physio-chemical correlates of alcohol intoxication. Neuropharmacology 1977;17:451-461.
7. Bushara KO, Goldstein SR, Grimes GJ, Burstein AH, Hallett M. Pilot trial of 1-octanol in essential tremor. Neurology 2004;62:122-124.
8. Shill HA, Reich M, Bushara KO, Grimes G, Hallett M. Dose-escalation study of 1-octanol in patients with essential tremor. Mov Disord 2002;17(suppl 5):S346. Abstract.
9. Bain PG, Findley LJ, Atchison P, et al. Assessing tremor severity. J Neurol Neurosurg Psychiatry 1993;56:868-873.
10. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 1998;54:251-264.